Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Item
http://www.wikidata.org/entity/Q38113507
Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis RecommendationsIs newer safer? Adverse events associated with first-line therapies for ANCA-associated vasculitis and lupus nephritis.Pneumocystis jiroveci prophylaxis in patients undergoing Bendamustine treatment: the need for a standardized protocol.Infection Risk and Safety of Corticosteroid Use.Key advances in the clinical approach to ANCA-associated vasculitis.B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease.Antibody-Independent Function of Human B Cells Contributes to Antifungal T Cell Responses.Long-term safety and efficacy of rituximab in 7 Japanese patients with ANCA-associated vasculitis.
P2860

Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?

Item
http://www.wikidata.org/entity/Q38113507
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Should Pneumocystis jiroveci p ...... in ANCA-associated vasculitis?
@en
type
label
Should Pneumocystis jiroveci p ...... in ANCA-associated vasculitis?
@en
prefLabel
Should Pneumocystis jiroveci p ...... in ANCA-associated vasculitis?
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P356
P1433
P1476
Should Pneumocystis jiroveci p ...... in ANCA-associated vasculitis?
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698